Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20110002.Her2HRneg

— · D

795922f0-611d-54cb-bb01-9337b2a15cca

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.670
  • INTERFERON_GAMMA_RESPONSE+0.670
  • ALLOGRAFT_REJECTION+0.650
  • IL6_JAK_STAT3_SIGNALING+0.570
  • INFLAMMATORY_RESPONSE+0.520
  • COMPLEMENT+0.440
  • KRAS_SIGNALING_UP+0.420
  • TNFA_SIGNALING_VIA_NFKB+0.420
  • IL2_STAT5_SIGNALING+0.390
  • PROTEIN_SECRETION+0.350

Top 10 suppressed

  • MYC_TARGETS_V2-0.530
  • NOTCH_SIGNALING-0.350
  • ESTROGEN_RESPONSE_EARLY-0.280
  • MYOGENESIS-0.230
  • WNT_BETA_CATENIN_SIGNALING-0.210
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
  • HEDGEHOG_SIGNALING-0.160
  • UNFOLDED_PROTEIN_RESPONSE-0.120
  • APICAL_JUNCTION-0.110
  • ADIPOGENESIS-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020049.LumB
breast-umap@18
—D0.906
2SRR5088852
melanoma-umap@29
——0.895
3b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc
melanoma-umap@29
——0.871
4TCGA-75-5122-01A-01R-1755-07
lung-landscapes@6
—cohortA10.870
5SRR8518312
breast-umap@18
—D0.868
6SRR12696798
melanoma-umap@29
——0.847
7SAMN03290949
melanoma-umap@29
——0.845
820030050.Her2HRneg
breast-umap@18
—D0.840
9SRR8518244
breast-umap@18
—D0.839
10SRR8518287
breast-umap@18
—C0.836

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.670Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.670Idelalisib— uncovered
ALLOGRAFT_REJECTION0.650Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.570Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.520Idelalisib— uncovered
COMPLEMENT0.440Inavolisib— uncovered
KRAS_SIGNALING_UP0.420Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.420Inavolisib— uncovered
IL2_STAT5_SIGNALING0.390Idelalisib— uncovered
PROTEIN_SECRETION0.350Remibrutinib— uncovered
APOPTOSIS0.320Idelalisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
MTORC1_SIGNALING0.290Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.290Inavolisib— uncovered
G2M_CHECKPOINT0.230Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.220Remibrutinib— uncovered
COAGULATION0.210Binimetinib— uncovered
XENOBIOTIC_METABOLISM0.190Inavolisib— uncovered
FATTY_ACID_METABOLISM0.170Inavolisib— uncovered